#USA #Fremont #Alamar Biosciences #NULISAqpcr #Alzheimer’s Research

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217

Alamar Biosciences, a leading company in precise proteomics for early disease detection, has made headlines with its recent introduction of the NULISAqpcr™ BD-pTau217 test. This innovative blood test aims to revolutionize the detection of brain-specific biomarkers pivotal in Alzheimer’s disease and other tauopathies, marking a significant advancement in neurodegenerative disease research.

Key Features of the NULISAqpcr™ BD-pTau217 Test

The NULISAqpcr™ BD-pTau217 is the first test of its kind, offering an unparalleled measurement of phosphorylated tau 217 (pTau217) derived from brain sources through blood samples. This non-invasive solution promises to set new standards in accuracy and specificity for Central Nervous System (CNS) research, facilitating critical advancements in understanding neurodegenerative diseases without the need for invasive procedures such as lumbar punctures or PET imaging.

“Our NULISAqpcr BD-pTau217 test redefines how we quantify CNS biomarkers,” claims Dr. Yuling Luo, founder, chairman, and CEO of Alamar Biosciences. By filtering out noise from peripheral sources of tau protein, researchers can now detect significant changes in the brain earlier and with greater precision.

Validation and Promising Results

Prominent neurologist Jonathan Schott, MD, PhD, from University College London, gives high praise to the performance of Alamar’s brain-specific plasma pTau217 tests. Preliminary findings suggest that this multiplex format detects Alzheimer’s pathology in cognitive symptom carriers with at least equal effectiveness to established plasma pTau217 tests, yet leads to fewer samples being classified in the ambiguous range. This innovation holds great promise for identifying asymptomatic individuals who may exhibit high levels of Alzheimer’s pathology, making them prime candidates for clinical trials of effective therapeutic interventions.

Streamlined Operations for Researchers

The BD-pTau217 test is available as a standalone NULISAqpcr test or within the multiplex NULISAseq™ CNS Disease Panel 120, supporting both discovery and translational research. With automated processes allowing for the processing of over 220 samples daily using the ARGO™ HT system, it is ideally suited for high-throughput analysis in disease cohorts or population studies.

Alamar Biosciences continues its collaboration with the neuroscience community to uncover biomarker insights that accelerate therapeutic advancements against Alzheimer’s disease and other related conditions. More details can be found at alamarbio.com.

Research Context and Future Prospects

The NULISA BD-pTau217 assays are designed exclusively for research purposes and are not intended for diagnostic use. Alamar Biosciences is committed to ensuring that it spearheads innovation within biomarker research towards the early detection of diseases.

In summary, the NULISAqpcr™ BD-pTau217 test represents a significant step forward in Alzheimer's research, blending advanced technology with practical application to foster a deeper understanding of this devastating disease.